ArticleAesthetic plastic surgery2026
Effect of Tranexamic Acid to Reduce Postoperative Hematoma in Reduction Mammaplasty: A Retrospective Analysis of 656 Patients.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative hematoma requiring reoperation is a clinically significant complication in breast surgery. Although tranexamic acid (TXA) is widely used in other surgical specialties to reduce bleeding, its routine use in breast surgery remains limited due to insufficient evidence. AIMS AND
objectivesThis study aimed to evaluate whether intraoperative TXA reduces the incidence of hematoma following reduction mammaplasty. MATERIALS AND
methodsWe conducted a retrospective, single-center cohort study including 656 consecutive patients who underwent reduction mammaplasty between 2019 and 2024. TXA was administered intravenously (n = 124, 43%), topically (n = 124, 43%), or via both routes (n = 39, 14%) according to surgeon preference. Patients exposed to TXA were compared with those unexposed.
resultsTXA use was associated with a significantly lower rate of postoperative hematomas requiring reoperation (2.1% vs. 5.1%; OR 2.3, 95% CI: 1.1-5.0; p = 0.042). Operative time was longer in the TXA group (133 vs. 122 minutes; p < 0.001), and patients receiving TXA had higher intraoperative blood loss and breast resection weights. No significant differences were observed in overall complications or 30-day reoperation rates, although superficial infections were more frequent in the non-TXA group (3.8% vs. 0.7%; p = 0.022). Multivariable analysis suggested a trend toward TXA as an independent protective factor. No TXA-related adverse events were reported.
conclusionsIntraoperative TXA in reduction mammaplasty was associated with a more than twofold reduction in postoperative hematomas. As a simple and low-risk intervention, TXA may reduce the need for reoperation. Large randomized controlled trials are warranted to confirm these findings and guide definitive clinical recommendations. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.